Overview

Vaccine Therapy in Treating Patients With Metastatic Melanoma of the Eye

Status:
Completed
Trial end date:
2007-03-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Vaccines may make the body build an immune response to kill tumor cells. Combining vaccine therapy with interleukin-2 may be a more effective treatment for metastatic melanoma of the eye. PURPOSE: Phase II trial to study the effectiveness of vaccine therapy and interleukin-2 in treating patients who have metastatic melanoma of the eye.
Phase:
Phase 2
Details
Lead Sponsor:
National Cancer Institute (NCI)
Treatments:
Freund's Adjuvant
Interleukin-2